NxStage Medical Inc. (NASDAQ:NXTM) has received a consensus rating of “Buy” from the nine research firms that are currently covering the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $26.33.
NXTM has been the topic of a number of analyst reports. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Wednesday, July 6th. Northland Securities set a $25.00 price target on NxStage Medical and gave the stock a “buy” rating in a research report on Thursday, September 15th. BTIG Research reissued a “buy” rating and set a $29.00 price target on shares of NxStage Medical in a research report on Sunday, August 7th. Jefferies Group increased their price target on NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Finally, Canaccord Genuity raised their target price on NxStage Medical from $22.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd.
In other news, Director Craig W. Moore sold 3,000 shares of the stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $23.31, for a total value of $69,930.00. Following the completion of the transaction, the director now directly owns 90,739 shares in the company, valued at approximately $2,115,126.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.70% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of NxStage Medical by 67.6% in the second quarter. FMR LLC now owns 7,537,811 shares of the medical device company’s stock worth $163,420,000 after buying an additional 3,040,601 shares during the last quarter. Perceptive Advisors LLC purchased a new position in shares of NxStage Medical during the second quarter worth approximately $29,971,000. Deerfield Management Co. boosted its position in shares of NxStage Medical by 20.0% in the first quarter. Deerfield Management Co. now owns 5,506,028 shares of the medical device company’s stock worth $82,535,000 after buying an additional 917,028 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of NxStage Medical during the second quarter worth approximately $14,911,000. Finally, Vanguard Group Inc. boosted its position in shares of NxStage Medical by 11.6% in the second quarter. Vanguard Group Inc. now owns 4,602,539 shares of the medical device company’s stock worth $99,783,000 after buying an additional 478,459 shares during the last quarter. Institutional investors own 98.26% of the company’s stock.
NxStage Medical (NASDAQ:NXTM) traded down 0.520% during midday trading on Wednesday, hitting $23.895. The stock had a trading volume of 39,967 shares. The company’s 50-day moving average price is $24.07 and its 200 day moving average price is $20.96. NxStage Medical has a 52 week low of $13.49 and a 52 week high of $26.07. The company’s market capitalization is $1.54 billion.
NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings results on Thursday, August 4th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.01. The business had revenue of $92.20 million for the quarter, compared to the consensus estimate of $89.44 million. NxStage Medical had a negative return on equity of 3.79% and a negative net margin of 2.06%. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.08) earnings per share. On average, analysts expect that NxStage Medical will post ($0.12) EPS for the current year.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.